Table 1.

Reported drug resistance in bone sarcoma CSCs.

Method of CSC Isolation/Characterization	Bone Sarcoma Models	Drug Resistance		Ref.
		Drug	Fold Resistance *
Sphere formation	MNNG/HOS (OS)	DOX CIS MTX	2.67 2.23 8.33	[49]
	MG63 (OS), HTB166 (EWS)	DOX CIS	N/Q N/Q	[44]
CD133	Human primary, Saos2, MG63, U2OS, HOS, MNNG/HOS, 143B (OS)	DOX CIS MTX	N/Q N/Q N/Q	[45]
	Human primary, STA-ET8.2, TC71, A4573, 5838 and other 5 lines (EWS)	DOX ETO VNC	N/Q N/Q N/Q	[48]
STRO-1/CD177	318-1, K7M2 (OS)	DOX	1.47, 1.73	[42]
CD271	Saos2, U2OS, MNNG/HOS (OS)	CIS	2.16, 1.42, 1.65	[51]
	Saos2, MNNG/HOS (OS)	CIS EPR	N/Q N/Q	[57]
CD24	Human primary, MG63, MNNG/HOS, U2OS, OSC228 (OS)	CIS EPR	N/Q N/Q	[58]
CD49f	UT2, TTC606 (OS)	CIS IDR PTX	6.56, >1.74 1.77, NA 2.10, NA	[55]
Side population	OS1, OS2, OS5 (Human Primary, OS)	DOX CIS MTX	1.33, 1.8, 1.67 1.09, 2.01, 1.07 1.46, 1.43, 0.94	[53]
	Human primary (OS)	DOX CIS MTX	N/Q N/Q N/Q	[50]
	OS65 (OS)	ETO 5-FU CIS PTX GEM OXP	N/Q N/Q N/Q N/Q N/Q N/Q	[52]
	SK-ES-1 (EWS)	DOX CIS	1.64 1.92	[54]
	CADO-ES1 (EWS)	DOX CIS ETO	N/Q N/Q N/Q	[47]
ALDH activity	Human primary (OS/CDS/EWS)	DOX DSF	N/Q N/Q	[46]
	Human primary, TC71, MHH-ES, SK-ES-1, A4573 (EWS)	DOX ETO	N/Q N/Q	[43]
hTERT	Human primary, MG63, MNNG/HOS, 143B (OS)	DOX	N/Q	[56]

* Fold resistance = IC₅₀ CSCs/IC₅₀ non-CSCs; OS: osteosarcoma, EWS: ewing sarcoma, CDS: chondrosarcoma, DOX: doxorubicin, CIS: cisplatin, MTX: methotrexate ETO: etoposide, VNC: vincristine, EPR: epirubicin, IDR: idarubicin, PTX: paclitaxel, GEM: gemcitabine, OXP: oxaliplatin, DSF: Disulfiram; N/Q: IC₅₀ Not quantified.